JARID1A : a Novel Oncology Therapeutic Target.

Many cancers can be attributed to alterations and mutations in tumor suppressor proteins. JARID1A (Jumonji, AT-rich interactive domain 1A) also recognized as RBP2 and RBBP2 is a ubiquitously expressed nuclear protein. JARID1A binds to the retinoblastoma protein (RB) variants that modulate cellular transcription and molecular proliferation/differentiation.  JARID1A has also been shown to interact with rhombotin-2, a protein implicated in T-cell mediated leukemia.

JARID1B also recognized as PLU-1 has been shown to block terminal differentiation altering cell fate.

JARID1B is over-expressed in many breast cancers and may modulate the BRCA1 and HOXA5 tumor suppressors. 

 

Description/Details

The cell lines created by the inventor contain vectors for study of JARID1A and JARID1B biological function. The inventor has created six MCF-7 cell line derivatives and six MDA-MB-231 cell line derivatives. Each set of stably transfected cell lines contain vectors for inducible expression of shRNA for either RB, JARID1A or JARID1B. Control cell line derivatives for Tet-Off-inducible expression and  Dox-inducible expression for both MCF-7 and MDA-MB-231 cell lines are included in the set. 

 

Applications

In vitro and xenograph studies of JARID1A and JARID1B  in the human breast cancer cell line MCF-7 cell or in the human breast cancer cell line MDA-MB-231.

 

Benefits

Convenient tetracycline inducible expression and doxycycline inducible expression cell systems

Stable transfected breast cancer cell lines for studying the cancer implicated proteins JARID1A and JARID1B biological function.  

 

Inventor Name

Elizaveta V. Benevolenskaya

Reference #

DE054
DE055
DE056
DE057
DE058
DE059
DE060
DE061
DE062
DE063
DE064
DE065
DE066
DE067
DE068
DE069
print